Project Grant R01AI195717
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $684,921 Project Grant to the University of Louisville on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the development of novel antiviral therapeutics targeting arthritogenic alphaviruses, with particular focus on Chikungunya virus and Old World alphavirus strains. The five-year project, scheduled for completion by August 31, 2030,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $227,115 to The Research Foundation For The State University Of New York (RF-SUNY at the University at Albany) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 3, 2026, with a completion date of January 31, 2028. This Project Grant supports investigator-initiated biomedical research aimed at elucidating the molecular mechanisms of Zika virus (ZIKV)...
- Federal Project Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $781,718 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 1, 2025 through May 31, 2030. The award supports the development of a novel T cell-based vaccine designed to prevent dengue virus (DENV) and Zika virus (ZIKV) infection while avoiding antibody-dependent enhancement...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston University Medical Campus a $449,625 Project Grant on July 8, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance research on arthropod-borne viral transmission mechanisms. This two-year project, concluding July 7, 2027, will deliver a novel preclinical research model designed to better understand how mosquito feeding and arthropod-mediated...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $200,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 4, 2026, with completion targeted for January 31, 2028. The award supports investigator-initiated biomedical research investigating the ubiquitin ligase TRIM39 protein and its role in controlling Zika virus (ZIKV)...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Trustees of Boston University $808,919 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 18, 2025, for a project period through August 31, 2030. This R01 Project Grant supports the development of novel aglain derivatives as host-targeted antiviral therapeutics against dengue virus (DENV) and other mosquito-borne arboviruses. The research addresses a...
- Federal Project Grant Award Summary The University of Louisville's Office of Research & Innovation received a $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) on September 4, 2025, with a completion date of August 31, 2029. This award supports fundamental biomedical research investigating a novel interaction between alphaviral capsid proteins and the host IRAK1 protein to...
- Grant Award Summary The University of Chicago received a $442,296 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of June 9, 2026 and completion date of May 31, 2028. The grant supports the development of RNA-degrading chimeras (RDCs)—a novel class of antiviral molecules designed to selectively bind viral RNA and cleave it directly through acid-base catalysis,...
- Federal Grant Award Summary Howard University received a $154,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 13, 2025, with a completion date of July 31, 2029. This award supports comprehensive biomedical research aimed at unveiling the mechanisms of Zika virus (ZIKV)-induced cardiac dysfunction in a neonatal mouse model. The research will employ both in vitro and in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Washington University a Project Grant of $155,454 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025, through July 31, 2027. This award funds research to identify and characterize molecular mechanisms of Venezuelan Equine Encephalitis Virus (VEEV) entry into host cells and to develop enhanced therapeutic interventions targeting...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Louisville $627,625 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 10, 2026, for a project concluding May 31, 2031. This Project Grant supports the development of novel antiviral therapeutics targeting Zika virus (ZIKV) by optimizing a benzamide-scaffold small-molecule series identified through cell-based ultra-high-throughput screening. The primary deliverables include a preclinical therapeutic candidate and backup compound demonstrating potency against ZIKV with favorable pharmacokinetic, pharmacodynamic, and toxicity profiles suitable for oral administration in mouse efficacy models. The research addresses urgent public health needs by targeting the ZIKV NS4B protein, which is essential for viral replication and represents a gap in current antiviral treatment options. Key project objectives encompass optimizing the lead benzamide compound for potency and drug-likeness, establishing mechanism-of-action through structural and biochemical approaches, and evaluating therapeutic efficacy and safety in preclinical animal models. The anticipated outcomes will generate scientific knowledge and a therapeutic candidate intended to reduce symptom severity and minimize vertical and community transmission of ZIKV, contributing to improved public health protection against this emerging pathogen.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $627.6k | 6/10/26 |